Andersen-Tawil syndrome pathophysiology

Jump to navigation Jump to search

Andersen-Tawil syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Andersen-Tawil syndrome from other Diseases

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Andersen-Tawil syndrome pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Andersen-Tawil syndrome pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Andersen-Tawil syndrome pathophysiology

CDC on Andersen-Tawil syndrome pathophysiology

Andersen-Tawil syndrome pathophysiology in the news

Blogs on Andersen-Tawil syndrome pathophysiology

Directions to Hospitals Treating Andersen-Tawil syndrome

Risk calculators and risk factors for Andersen-Tawil syndrome pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

It is understood that Andersen-Tawil syndrome is the result of mutation in KCNJ2 gene which encodes for Kir2.1 inward rectifier potassium channel that involves in cardiac repolarization phase. The movement of potassium ions through these channels is critical for maintaining the normal functions of skeletal muscles which are used for movement and cardiac muscle. Andersen-Tawil syndrome is a rare syndrome transmitted in autosomal dominant pattern.

Pathophysiology

Pathogenesis

Genetics

Associated Conditions

Conditions associated with Andersen-Tawil syndrome include:[12][13]

References

  1. Limberg MM, Zumhagen S, Netter MF, Coffey AJ, Grace A, Rogers J; et al. (2013). "Non dominant-negative KCNJ2 gene mutations leading to Andersen-Tawil syndrome with an isolated cardiac phenotype". Basic Res Cardiol. 108 (3): 353. doi:10.1007/s00395-013-0353-1. PMID 23644778.
  2. Doi T, Makiyama T, Morimoto T, Haruna Y, Tsuji K, Ohno S; et al. (2011). "A novel KCNJ2 nonsense mutation, S369X, impedes trafficking and causes a limited form of Andersen-Tawil syndrome". Circ Cardiovasc Genet. 4 (3): 253–60. doi:10.1161/CIRCGENETICS.110.958157. PMID 21493816.
  3. Tan SV, Z'graggen WJ, Boërio D; et al. (2012). "Membrane dysfunction in Andersen-Tawil syndrome assessed by velocity recovery cycles". Muscle Nerve. 46 (2): 193–203. doi:10.1002/mus.23293. PMID 22806368. Unknown parameter |month= ignored (help)
  4. Tristani-Firouzi M, Etheridge SP (2010). "Kir 2.1 channelopathies: the Andersen-Tawil syndrome". Pflugers Arch. 460 (2): 289–94. doi:10.1007/s00424-010-0820-6. PMID 20306271.
  5. Plaster NM, Tawil R, Tristani-Firouzi M, Canún S, Bendahhou S, Tsunoda A; et al. (2001). "Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome". Cell. 105 (4): 511–9. doi:10.1016/s0092-8674(01)00342-7. PMID 11371347.
  6. Haruna Y, Kobori A, Makiyama T, Yoshida H, Akao M, Doi T; et al. (2007). "Genotype-phenotype correlations of KCNJ2 mutations in Japanese patients with Andersen-Tawil syndrome". Hum Mutat. 28 (2): 208. doi:10.1002/humu.9483. PMID 17221872.
  7. Ballester LY, Benson DW, Wong B, Law IH, Mathews KD, Vanoye CG; et al. (2006). "Trafficking-competent and trafficking-defective KCNJ2 mutations in Andersen syndrome". Hum Mutat. 27 (4): 388. doi:10.1002/humu.9418. PMID 16541386.
  8. Tristani-Firouzi M, Jensen JL, Donaldson MR; et al. (2002). "Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome)". J. Clin. Invest. 110 (3): 381–8. PMID 12163457.
  9. Pegan S, Arrabit C, Slesinger PA, Choe S (2006). "Andersen's syndrome mutation effects on the structure and assembly of the cytoplasmic domains of Kir2.1". Biochemistry. 45 (28): 8599–606. doi:10.1021/bi060653d. PMID 16834334.
  10. Sansone V, Tawil R (2007). "Management and treatment of Andersen-Tawil syndrome (ATS)". Neurotherapeutics. 4 (2): 233–7. doi:10.1016/j.nurt.2007.01.005. PMID 17395133.
  11. Nguyen HL, Pieper GH, Wilders R (2013). "Andersen-Tawil syndrome: clinical and molecular aspects". Int J Cardiol. 170 (1): 1–16. doi:10.1016/j.ijcard.2013.10.010. PMID 24383070.
  12. Andersen, Ellen Damgaard; Krasilnikoff, Peter A.; Overvad, Hans (1971). "INTERMITTENT MUSCULAR WEAKNESS, EXTRASYSTOLES, AND MULTIPLE DEVELOPMENTAL ANOMALIES". Acta Paediatrica. 60 (5): 559–564. doi:10.1111/j.1651-2227.1971.tb06990.x. ISSN 0803-5253.
  13. Schoonderwoerd, Bas A.; Wiesfeld, Ans C.P.; Wilde, Arthur A.M.; van den Heuvel, Freek; Van Tintelen, J. Peter; van den Berg, Maarten P.; Van Veldhuisen, Dirk J.; Van Gelder, Isabelle C. (2006). "A family with Andersen-Tawil syndrome and dilated cardiomyopathy". Heart Rhythm. 3 (11): 1346–1350. doi:10.1016/j.hrthm.2006.07.021. ISSN 1547-5271.


Template:WikiDoc Sources